Last reviewed · How we verify
FOLFOX4
At a glance
| Generic name | FOLFOX4 |
|---|---|
| Also known as | Oxaliplatin plus Fluorouracil/Leucovorin, Oxaliplatin + leucovorin + 5-FU, FOLFOX4 (leucovorin + fluorouracil + oxaliplatin), Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid), Oxaliplatin, Leucovorin, 5-Fluorouracil |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2,PHASE3)
- A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (PHASE2)
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (PHASE2)
- Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (PHASE2)
- Immunotherapy for Advanced Liver Cancer (PHASE2,PHASE3)
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (PHASE2)
- Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old (PHASE3)
- Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX4 CI brief — competitive landscape report
- FOLFOX4 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI